Replies to post #171457 on Biotech Values

[oc631]

The bearish argument against ABBV is that with these results they do not have a credible "natural" positioning strategy in the market and will need to compete more heavily on price.

You read my commentary on this MB. You are preaching to the choir.

[oc631]

The bearish argument against ABBV is that with these results they do not have a credible "natural" positioning strategy in the market and will need to compete more heavily on price.

I just need some clarification. Did you mean to say GILD doesn't have a positioning strategy? I thought this was an inadvertent error so I didn't question it. GILD has the issue of keeping Sofo/Riba pricing at a premium while competing on price with ABBV using the more complex Sofo/Ledi combo in GT1.

[DewDiligence]

No doubt about it—pricing in going to play a big role in how this market shakes out. Outside the US, this will be true to an even greater extent.